← Back to Clinical Trials
Recruiting NCT06077019

NCT06077019 Role of Lung Function for Exercise Capacity in Well-trained Individuals

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06077019
Status Recruiting
Phase
Sponsor Morten Hostrup, PhD
Condition Exercise Performance
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2023-10-03
Primary Completion 2026-07-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 39 Years
Study Type INTERVENTIONAL
Interventions
Vilanterol and Fluticasone FuroateIndacaterol and Mometasone FuroatePlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2023-10-03 with a primary completion date of 2026-07-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the project is to investigate exercise performance in humans following prolonged inhalation of beta2-agonists vilanterol + fluticasone furoate or indacaterol + mometasone furoate

Eligibility Criteria

Inclusion Criteria: * Age 18-39 * Physically active \> 5 h weekly * Maximal oxygen consumption classified as high or very high Exclusion Criteria: * Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid * ECG abnormality * ACQ score \> 1.5 * Severe bronchial hyperreactivity as determined by mannitol test * FEV1/FVC ratio \< 0.7 determined with spirometry * Chronic illness determined to be a potential risk for participant during study * In chronic treatment with medication that may interfere with study results * Pregnancy * Smoker * Blood donation during the past 3 months

Contact & Investigator

Central Contact

Morten Hostrup, PhD

✉ mhostrup@nexs.ku.dk

📞 +4535321595

Principal Investigator

Morten Hostrup, PhD

PRINCIPAL INVESTIGATOR

University of Copenhagen

Frequently Asked Questions

Who can join the NCT06077019 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Exercise Performance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06077019 currently recruiting?

Yes, NCT06077019 is actively recruiting participants. Contact the research team at mhostrup@nexs.ku.dk for enrollment information.

Where is the NCT06077019 trial being conducted?

This trial is being conducted at Copenhagen, Denmark.

Who is sponsoring the NCT06077019 clinical trial?

NCT06077019 is sponsored by Morten Hostrup, PhD. The principal investigator is Morten Hostrup, PhD at University of Copenhagen. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology